If you're taking a GLP-1 medication like Ozempic, Wegovy, or Mounjaro, you may have heard whispers about thyroid risks. Let's cut through the noise and look at what the science actually says.
Wondering about GLP-1 and thyroid function? Learn the real risks, who should be cautious, and what monitoring you need while on these medications.
What Is GLP-1 and How Does It Work?
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It tells your pancreas to release insulin, slows down digestion, and sends fullness signals to your brain. GLP-1 medications mimic this hormone, helping people with type 2 diabetes and obesity manage blood sugar and lose weight.
These medications include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity).
Acompanhe seus exames e veja o impacto do protocolo nos biomarcadores.
Registrar no appThe Thyroid Connection: What Research Shows
Here's where things get interesting. GLP-1 receptors are found in the thyroid gland, particularly in cells called C-cells that produce calcitonin. In rodent studies, long-term exposure to GLP-1 medications caused thyroid tumors. However, the relevance to humans has not been conclusively established.
What we know from human data:
- Cases of thyroid cancer have been reported in patients using GLP-1 medications, but the absolute risk appears very low
- The FDA added a boxed warning to certain GLP-1 medications about potential thyroid C-cell tumors
- Most cases occurred in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2)
Who Should Be Concerned About Thyroid Risks?
Not everyone needs to panic. The people who should be most cautious include those with:
- A personal history of medullary thyroid carcinoma (MTC)
- A family history of MTC or MEN2 syndrome
- Anyone with a genetic predisposition to thyroid cancers
